References
- Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, . Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007;298: 1763–71.
- Fowler VG, Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, . Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005;293:3012–21.
- Miro JM, Anguera I, Cabell CH, Chen AY, Stafford JA, Corey GR, . Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis 2005;41:507–14.
- Nathwani D, Morgan M, Masterton RG, Dryden M, Cookson BD, French G, . Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother 2008;61:976–94.
- Maclayton DO, Hall RG 2nd. Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus. Ann Pharmacother 2007; 41:235–44.
- Rybak MJ, Lomaestro BM, Rotscahfer JC, Moellering RC, Craig WA, Billeter M, . Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009;49:325.
- Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, . Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52:e18–55.
- Chang FY, Peacock JE Jr, Musher DM, Triplett P, MacDonald BB, Mylotte JM, . Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003;82:333.
- Silverman JA, Mortin LI, Van Praagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005;191:2149.
- Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother 2009;53: 4069–79.
- Schaison G, Graninger W, Bouza E. Teicoplanin in the treatment of serious infection. J Chemother 2000;12:26–33.
- Murray BE, Nannini EC. Glycopeptides (teicoplanin and vancomycin), streptogramins (quinupristin–dalfopristin), and lipopeptides (daptomycin). In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's principles and practice of infectious diseases. Vol. 1. 7th ed. Philadelphia: Elsevier Inc.; 2010 pp. 449–67.
- Cavalcanti AB, Goncalves AR, Almeida CS, Bugano DD, Silva E. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev 2010(6):CD007022.